RP11-165M6.1: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

Target Name: LINC00460

NCBI ID: G728192

LINC00460

Other Name(s): RP11-165M6.1 | long intergenic non-protein coding RNA 460 | Long intergenic non-protein coding RNA 460, transcript variant 1

RP11-165M6.1: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

LINC00460 (RP11-165M6.1) is a non-coding RNA molecule that has been identified as a potential drug target (RP11-165M6.1) and a biomarker for various diseases, including cancer. LINC00460 is a key regulator of gene expression in many organisms, and its levels have been shown to be altered in a wide range of diseases and conditions.

The RP11-165M6.1 gene is located on chromosome 16 and has been shown to encode a protein that is involved in the regulation of cell adhesion and migration. The protein encoded by this gene is a member of the cadherin family, which is a well-known family of transmembrane proteins that are involved in cell-cell adhesion.

Studies have shown that LINC00460 is highly expressed in many tissues and organs, including brain, heart, liver, and muscle. It has also been shown to be involved in the regulation of cellular processes that are important for normal development and maintenance of tissues and organs.

One of the most promising aspects of LINC00460 is its potential as a drug target. The RP11-165M6.1 gene has been shown to be involved in the regulation of cell adhesion and migration, which are important processes that are involved in the development of many diseases, including cancer. Therefore, it is possible that LINC00460 could be a useful target for the development of drugs that can inhibit the growth and progression of cancer.

In addition to its potential as a drug target, LINC00460 has also been shown to be a potential biomarker for a wide range of diseases. The RP11-165M6.1 gene has been shown to be involved in the regulation of cellular processes that are important for normal development and maintenance of tissues and organs. Therefore, it is possible that LINC00460 could be a useful biomarker for diseases that are characterized by abnormal cellular processes, such as cancer.

RP11-165M6.1 is a non-coding RNA molecule, meaning that it does not encode a protein, but rather it regulates the expression of other genes. It is important to note that the regulation of gene expression is a complex process that is still not fully understood. LINC00460 is a key regulator of gene expression and its levels have been shown to be altered in a wide range of diseases and conditions.

RP11-165M6.1 has been shown to be involved in the regulation of cellular processes that are important for normal development and maintenance of tissues and organs. It is possible that LINC00460 could be a useful target for the development of drugs that can inhibit the growth and progression of cancer, as well as for the diagnosis and treatment of diseases that are characterized by abnormal cellular processes.

In conclusion, LINC00460 is a non-coding RNA molecule that has been identified as a potential drug target (RP11-165M6.1) and a biomarker for various diseases, including cancer. Its levels have been shown to be altered in a wide range of diseases and conditions, and its potential as a drug target and biomarker is under further investigation. Further studies are needed to determine the full extent of its potential and to develop safe and effective drugs that can inhibit its activity.

Protein Name: Long Intergenic Non-protein Coding RNA 460

The "LINC00460 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00460 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets